Orpheris, Inc. logo

Orpheris, Inc.

Orpheris' technology platform consists of hydroxyl dendrimers that specifically target activated microglia and reactive astrocytes associated with neuroinflammation resulting in demyelination and neuronal loss.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://orpheris.com
Disease Focus
STOCK CODENon Listed
Address
303 Twin Dolphin Drive, Suite 600, CA 94065
Redwood City
United States
Email
Contact Number
+1 650-249-6290

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]